2024
Sleep disturbance, suicidal ideation and psychosis-risk symptoms in individuals at clinical high risk for psychosis
Cohen S, Goldsmith D, Ning C, Addington J, Bearden C, Cadenhead K, Cannon T, Cornblatt B, Keshavan M, Mathalon D, Perkins D, Seidman L, Stone W, Tsuang M, Woods S, Walker E, Miller B. Sleep disturbance, suicidal ideation and psychosis-risk symptoms in individuals at clinical high risk for psychosis. Psychiatry Research 2024, 341: 116147. PMID: 39197223, DOI: 10.1016/j.psychres.2024.116147.Peer-Reviewed Original ResearchPsychosis-risk symptomsClinical high riskSuicidal ideationCHR-P individualsCHR-PSleep disturbanceTerminal insomniaNorth American Prodrome Longitudinal StudyAssociated with conversion to psychosisSleep problemsConversion to psychosisTreatment of sleep disturbancesAssociated with SIIndices of sleep disturbanceMultiple indicesPsychosisIdeationLongitudinal intervention studyInsomniaLongitudinal studySchizophreniaSymptomsSleepSymptom scoresInvestigate relationshipsSex differences in clinical presentation in youth at high risk for psychosis who transition to psychosis
Chintoh A, Liu L, Braun A, Akseer S, Bearden C, Cadenhead K, Cornblatt B, Keshavan M, Mathalon D, McGlashan T, Perkins D, Seidman L, Stone W, Tsuang M, Walker E, Woods S, Cannon T, Addington J. Sex differences in clinical presentation in youth at high risk for psychosis who transition to psychosis. Schizophrenia Research 2024, 271: 153-160. PMID: 39029145, DOI: 10.1016/j.schres.2024.07.030.Peer-Reviewed Original ResearchClinical high riskClinical high-risk individualsSex differencesNegative symptomsTransition to psychosisInvestigate sex differencesNo sex differencesSchizophreniform disorderCHR individualsPsychosisSubstance useSchizophreniaSymptomsHigh riskIndividualsSchizophreniformAnxietyClinical presentationSexDepressionDisordersBaselineDifferencesMaleYouth
2012
Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies
Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, Pearlson GD, Javitt DC, McGlashan TH, Krystal JH. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. European Neuropsychopharmacology 2012, 23: 931-940. PMID: 23089076, PMCID: PMC4028140, DOI: 10.1016/j.euroneuro.2012.09.008.Peer-Reviewed Original ResearchConceptsPilot studyRisk syndromeSyndrome patientsNegative symptomsShort-term pilot studyEffect sizeAdjunctive antipsychotic medicationOpen-label studyPatients meeting criteriaNMDA receptor functionDurability of effectPsychosis risk symptomsGlycine site agonistsGroup effect sizesWeeks of evaluationAntipsychotic medicationSyndrome subjectsPromising effect sizesTreatment needsLarge effect sizesMeeting criteriaCognitive impairmentReduced symptomsReceptor functionSymptoms